Details

Autor(en) / Beteiligte

• MOTOHIRO, TAKASHI
• TANAKA, KOICHI
• KOGA, TATSUHIKO
• SHIMADA, YASUSHI
• TOMITA, NAOFUMI
• SAKATA, YASUTAKA
• FUJIMOTO, TAMOTSU
• NISHIYAMA, TORU
• ISHIMOTO, KOJI
• TOMINAGA, KAORU
• YAMASHITA, FUMIO
• KOGA, YASUTOSHI
• SAKAGUCHI, YUSUKE
• TAKAJO, NOBUHIKO
• ARAKI, HISAAKI
• YOSHIMOTO, MASANAGA
• ITO, YUHEI
• OHBZU, KEIZO
• IMAI, SHOICHI
• NAGAYAMA, KIYOTAKA
• YUASA, TAKESHI
• TSUGAWA, SHIN
• ARAMAKI, SHUICHI
• OHTAKI, ETSUO
• IRIKI, TSUKASA
• CHO, HIROYUKI
• YAMAMOTO, MASASHI
• KOMATSU, YOSHIHARU
• TANAKA, CHIHEI
• TOYODA, ON
• YUGE, KEN
• KATO, EIJI
• HARADA, YUTAKA
• YUKIZANE, SHIGENORI
• TAKECHI, TETSUHISA
• OHTA, MASANORI
• MATSUO, HIROSHI
• HIRATA, KATSUHIKO
• ETO, YOSHIHARU
• MATSUYUKI, MAKADO
• KIMURA, YOSHIYUKI
• DAI, SHUNICHI
• KUDA, NAOKI
• ONO, EIICHIRO
• KATABUCHI, YUKIHIKO

Titel

FUNDAMENTAL AND CLINICAL STUDIES OF CEFTAZIDIME IN THE PEDIATRIC FIELD

Ist Teil von

• The Japanese Journal of Antibiotics, 1984/03/25, Vol.37(3), pp.537-553

Ort / Verlag

Japan: Japan Antibiotics Research Association

Erscheinungsjahr

1984

Quelle

MEDLINE

Beschreibungen/Notizen

• Ceftazidime (CAZ), a newly-developed parenteral cephem antibiotic, was administered to 8 children; by one shot intravenous (i.v.) injection in the doses of 20 and 40 mg/kg each to 2 children, and by 30 minutes' i.v. drip infusion in the doses of 10 and 20 mg/kg each to 2 children, and the serum levels, urinary levels and recovery rates were determined. CAZ was also administered to 2 patients with purulent meningitis, one complicated with subdural abscess and the other with bacteremia, in the doses of 19.2 and 50.7 mg/kg, respectively, by one shot i.v. injection, and the CSF level of CAZ was determined. In addition, CAZ was administered to 2 children with acute bronchitis, 1 with chronic bronchitis, 37 with pneumonia, 3 with pleuropneumonia, 1 each for purulent meningitis, purulent meningitis accompanied with subdural abscess and purulent meningitis with bacteremia, 5 with urinary tract infections and 3 with purulent lymphadenitis (total 54 children), in the mean dose of 85.8 mg/ kg/day mostly in 4 divided doses by one shot i.v. injection for 9 days on the average, and clinical effectiveness and bacteriological response were evaluated in these cases, and adverse events and abnormal laboratory findings were examined in the 66 cases which included 12 drop-out cases. 1. After the administration of CAZ to 4 children; 20 and 40 mg/kg each to 2 children, by one shot i.v. injection, the mean serum levels got to the peak of 115.8 and 199.5 mcg/ml, respectively, at 5 minutes. The results were good, showing dose response. The mean half-lives were 1.48 and 1.37 hours, respectively. After the administration of 10 and 20 mg/kg of CAZ each to 2 children by 30 minutes' i.v. drip infusion, the mean serum levels got to the peak of 58.5 and 80.0 mcg/ml, respectively, on completion of the administration, showing dose response. The mean half-lives were 1.06 hours in the former 2 cases, and 1.38 and 3.26 hours, respectively, in the latter 2 cases. The reason for the prolongation observed in 1 case was not clear. 2. In the above mentioned each 2 cases receiving one shot i.v. injection, the mean urinary levels got to the peak of 4,240 and 4,445 mcg/ml, respectively, at 0-2 hours after the administration, and the urinary recovery rates during the first 6 hours were high, 95.7% and 99.5%, respectively. In each 2 cases receiving 30 minutes' i.v. drip infusion, the peak urinary levels were obtained at 0-2 hours after the administration, the mean peak levels being 1,425 and 5,030 mcgiml, respectively, and the mean recovery rates during the first 6 hours were 85.3 and 93.2%, which were good results like those in the cases of one shot i.v. injection. 3. In the case of purulent meningitis accompanied with subdural abscess, treated with CAZ in the dose of 19.2 mg/kg by one shot i.v. injection on the 13th day of illness, the CSF level determined at 1.5 hours was 2.77 mcg/ml. In the case of purulent meningitis with bacteremia, treated with CAZ at 50.7 mg kg by one shot i.v. injection on the 4th day of illness, the CSF level was 10.2 mcg/ml, and the serum level, 72.6 mcg/ml at 1 hour after the administration, the ratio of the CSF level versus serum level being 14.0%. The CSF and serum levels were 6.32 and 66.9 mcg/ml, respectively, on the 15th day of illness, showing satisfactory transfer into the CSF of CAZ at the ratio of 9.45% to serum level. 4. As to the clinical effectiveness in 54 cases, 46 cases w ere assessed as excellent or good, which showed high efficacy rate of 85.2%. 5. The clinical efficacy classified by isolated organism could not be evaluated because the number of the cases for each isolated organism was insufficient for evaluation. 6. As to the overall bacteriological response, 11 out of 18 strains (61.1%) were eradicated.